Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monette

Showing results (681-690 of 740) with videos related to

Pageof 74
Sort By:
Blood Advances|January 27, 2022
IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphomaSuraya Elfrink, Martin Ter Beest, Luuk Janssen, et al.
Leukemia|July 27, 2017
Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapyZ Yao, L Deng, Z Y Xu-Monette, et al.
Blood Advances|July 30, 2020
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCLZijun Y Xu-Monette, Hongwei Zhang, Feng Zhu, et al.
Blood Advances|December 5, 2025
Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosisXue Kong, Zijun Y Xu-Monette, Zhenming Xu, et al.
Science Translational Medicine|April 21, 2017
RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injuryJulius C Fischer, Michael Bscheider, Gabriel Eisenkolb, et al.
Molecular Cancer Research : MCR|November 6, 2020
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted AgentsManman Deng, Zijun Y Xu-Monette, Lan V Pham, et al.
Journal for Immunotherapy of Cancer|October 24, 2019
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapiesZijun Y Xu-Monette, Jianyong Li, Yi Xia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Li Wei, Xiaosheng Fang, et al.
Oncotarget|November 18, 2015
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphomaQing Ye, Zijun Y Xu-Monette, Alexandar Tzankov, et al.
Blood|October 15, 2021
Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host diseaseMelissa D Docampo, Marina B da Silva, Amina Lazrak, et al.
Pageof 74

Showing results (681-690 of 740) with videos related to

Sort By:
Pageof 74
Blood Advances|January 27, 2022
IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphomaSuraya Elfrink, Martin Ter Beest, Luuk Janssen, et al.
Leukemia|July 27, 2017
Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapyZ Yao, L Deng, Z Y Xu-Monette, et al.
Blood Advances|July 30, 2020
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCLZijun Y Xu-Monette, Hongwei Zhang, Feng Zhu, et al.
Blood Advances|December 5, 2025
Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosisXue Kong, Zijun Y Xu-Monette, Zhenming Xu, et al.
Science Translational Medicine|April 21, 2017
RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injuryJulius C Fischer, Michael Bscheider, Gabriel Eisenkolb, et al.
Molecular Cancer Research : MCR|November 6, 2020
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted AgentsManman Deng, Zijun Y Xu-Monette, Lan V Pham, et al.
Journal for Immunotherapy of Cancer|October 24, 2019
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapiesZijun Y Xu-Monette, Jianyong Li, Yi Xia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Li Wei, Xiaosheng Fang, et al.
Oncotarget|November 18, 2015
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphomaQing Ye, Zijun Y Xu-Monette, Alexandar Tzankov, et al.
Blood|October 15, 2021
Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host diseaseMelissa D Docampo, Marina B da Silva, Amina Lazrak, et al.
Pageof 74